Compare Vaxcyte Inc. Common Stock (PCVX) vs Truist Financial Corporation Common Stock (TFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Truist Financial Corporation Common Stock — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Truist Financial Corporation Common Stock trades at $46.18 (market cap $56.10B). The key difference: Truist Financial Corporation Common Stock is far larger — about 5.3× Vaxcyte Inc. Common Stock's market cap, and Truist Financial Corporation Common Stock pays a 4.53% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Truist Financial Corporation Common Stock for 6 Days on average.
| PCVX | TFC | |
|---|---|---|
Market Cap | $10.51B | $56.10B |
Volume | 2,644,694 | 6,666,157 |
Sector | Health | Financials |
52-Week High | $73.82 | $55.81 |
52-Week Low | $40.32 | $41.09 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.14B | $122.36B |
Dividend Yield | — | 4.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Truist Financial (TFC) trades at $45.92, down 1.54% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the bank maintains solid profitability with 28.01% net income margin and attractive valuation at 10.56 P/E ratio. Recent earnings show beats in Q1 and Q2 2026, while Q3 results are pending. The company is executing strategic portfolio optimization including a $5.5B auto loan sale under new CEO Michael Lyons.
TFC presents a value opportunity with 17.6% upside to consensus price target of $54, supported by 50% analyst buy ratings. Key catalysts include Q3 earnings release on October 16 and ongoing business simplification. Risks include near-term net interest margin pressure and frozen dividend since 2022. The stock offers income investors a compelling risk-reward profile with improving credit quality and capital optimization initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Truist Financial Corporation Common Stock
Truist Financial provides consumer and commercial banking, wealth management, insurance, and investment services in the United States.
Read more on TFC →
